| dc.creator | Zarogoulidis P., Papadopoulos V., Maragouli E., Papatsibas G., Huang H. | en |
| dc.date.accessioned | 2023-01-31T11:38:20Z | |
| dc.date.available | 2023-01-31T11:38:20Z | |
| dc.date.issued | 2017 | |
| dc.identifier | 10.21037/jtd.2017.08.24 | |
| dc.identifier.issn | 20721439 | |
| dc.identifier.uri | http://hdl.handle.net/11615/80962 | |
| dc.description.abstract | [No abstract available] | en |
| dc.language.iso | en | en |
| dc.source | Journal of Thoracic Disease | en |
| dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85030119426&doi=10.21037%2fjtd.2017.08.24&partnerID=40&md5=df8a96ccfa2c0b8427898453a0da4ba8 | |
| dc.subject | anaplastic lymphoma kinase | en |
| dc.subject | epidermal growth factor receptor | en |
| dc.subject | nivolumab | en |
| dc.subject | osimertinib | en |
| dc.subject | pembrolizumab | en |
| dc.subject | programmed death 1 ligand 1 | en |
| dc.subject | protein tyrosine kinase inhibitor | en |
| dc.subject | cancer recurrence | en |
| dc.subject | cancer resistance | en |
| dc.subject | drug approval | en |
| dc.subject | Editorial | en |
| dc.subject | human | en |
| dc.subject | immunogenicity | en |
| dc.subject | malignant transformation | en |
| dc.subject | non small cell lung cancer | en |
| dc.subject | protein expression | en |
| dc.subject | small cell lung cancer | en |
| dc.subject | squamous cell lung carcinoma | en |
| dc.subject | tumor biopsy | en |
| dc.subject | AME Publishing Company | en |
| dc.title | Checkpoint inhibitors in metastatic epidermal growth factor receptor-mutated non-small cell lung cancer patients: Where we treating the wrong cancer? | en |
| dc.type | other | en |